McDonald’s or Pfizer: One Offers Real Growth, One Just Pays You to Wait

McDonald’s (NYSE:MCD | MCD Price Prediction) versus Pfizer (NYSE:PFE): which one deserves a place in a retirement-focused portfolio right now? Both are low-beta blue chips providing reliable quarterly checks, and both have lagged the broader market. The S&P 500 is up 20.5% over the past year, while McDonald’s has slipped 5.6% and Pfizer has pulled back 5.1%. Retirement investors buying either stock today are stepping in on flat, out-of-favor names. The question is which one pays you better to wait, and which one you can actually sleep on at night.

Why Both Have Lagged

McDonald’s has been weighed down by inflation-squeezed lower-income consumers, a higher effective tax rate (22.0% vs. 19.8% year-ago), and rising interest expense, even as U.S. comps recovered to +3.9% in Q1 2026. Pfizer, meanwhile, is grinding through a post-COVID reset: Comirnaty fell 59% and Paxlovid fell 63% operationally in Q1 2026, and management flagged a $1.5 billion unfavorable hit from generic and biosimilar competition in 2026. Add Most-Favored-Nation drug pricing and TrumpRx pressure, and the market’s caution becomes understandable.

Round 1: Yield and Valuation (Winner: Pfizer)

The valuation gap is wide. Pfizer yields 7.1% at a trailing P/E of 18 and a forward P/E near 8, with a free cash flow yield of 6.57%. McDonald’s yields 2.7% at a trailing P/E of 23 and a price-to-free-cash-flow above 27. A retiree deploying $250,000 collects roughly $17,875 a year from Pfizer versus about $6,425 from McDonald’s. If the mandate is income today, Pfizer writes the bigger check by a wide margin.

Round 2: Growth Trajectory (Winner: McDonald’s)

McDonald’s is quietly compounding. Full-year 2025 revenue grew 3.72%, operating income rose 5.81%, and free cash flow expanded 7.7% to $7.186 billion. Q1 2026 revenue climbed 9.4% and global comps hit +3.8%. Pfizer’s top line went the other way: FY2025 revenue fell 1.65%, and 2026 guidance of $59.5 to $62.5 billion in revenue and $2.80 to $3.00 in adjusted EPS points to another year of digestion. Pfizer’s launched and acquired products grew 22% operationally, but that only partially cushioned the COVID cliff.

_

Round 3: Dividend Safety and Track Record (Winner: McDonald’s)

McDonald’s is a Dividend Aristocrat. It raised its quarterly dividend through the 2008–2009 crisis, growing the payout past $1.25 through 2020, and it boosted the payout 5% in October 2025 to $1.86. Pfizer has not cut its dividend during its current multi-year streak of consecutive payments. The quarterly payout has crept from $0.42 to $0.43 between 2024 and 2026, a near-flat dividend paired with a $4.4 billion impairment charge in Q4 2025, a GAAP net loss that quarter, and no anticipated buybacks in 2026. (For dividend safety warnings that could hit an income portfolio, our Dividend Traps research is worth a look.)

The Verdict

McDonald’s wins overall for the retirement investor who wants total return, dividend growth, and a business they will not have to babysit through drug-pricing headlines. Two of the three rounds go to the Golden Arches, and the round Pfizer wins (income today) carries the exact risks retirees usually try to avoid: revenue declines, patent-cliff exposure, impairment charges, and a paused buyback.

Pfizer wins for one specific profile only: the income-focused retiree with a pension or Social Security floor who genuinely needs the 7.1% yield now, can tolerate a flat-to-shrinking share price, and treats the position as a bond substitute rather than a compounder. For everyone else building a retirement paycheck they want to grow, McDonald’s is the stronger fit.

Contact [email protected] for any questions or corrections._